$PNT News
Last published 4mo ago
- 4mo agoPNTEarnings Call - POINT BIOPHARMA GLOBAL INCEarnings Call TranscriptsHowdy folks, I'm Jake from Swoogo. Let's talk about event check-in and let's talk about an honest truth when it comes to event check in. If your check- in process is slow, it's noticeable and it's also going to affect th
- 5mo agoPNTHow to Personalize Event Registration With Conditional Logic - POINT BIOPHARMA GLOBAL INCEarnings Call TranscriptsHowdy folks, it's me again Jake from Swoogo. Hopefully you are not tired of me yet because we still have so much content to go through in the future so you are still stuck with me. Although hypothetically you could just
- 5mo agoPNTEarnings Call - POINT BIOPHARMA GLOBAL INCEarnings Call TranscriptsHowdy folks, it's me again Jake from Swoogo. Hopefully you are not tired of me yet because we still have so much content to go through in the future so you are still stuck with me. Although hypothetically you could just
- 6mo agoPNTEarnings Call - POINT BIOPHARMA GLOBAL INCEarnings Call TranscriptsHowdy folks, I'm Jake from Swoogo. So here's something that's probably happened to you more than you would like to admit. Someone on your team asks you questions about your event. How are registrations going? Is there st
- 6mo agoPNTEarnings Call - POINT BIOPHARMA GLOBAL INCEarnings Call TranscriptsHowdy folks, I'm Jake from Swoogo. So today I want to talk about Claude, probably one of the more popular and maybe your favorite AI tool or assistant or agent. I don't know quite where we are with terminology nowadays,
- 7mo agoPNTEarnings Call - POINT BIOPHARMA GLOBAL INCEarnings Call TranscriptsHowdy folks, I'm Jake from Swoogo. If your group registration is starting to feel a little bit like a spreadsheet nightmare, then we may need to take a look at what's going on. Group registration is supposed to make thin
- 2y agoACHVALGSDCTHPNTDelcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of DirectorsBusiness WireDelcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr.
- 2y agoLLYPNTLilly Completes Acquisition of POINT BiopharmaPR NewswireEli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a...
- 2y agoGMDAPNTPPBTSCNIPurple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsGlobeNewswireDr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT,
- 2y agoLNTHPNTLantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate CancerGlobeNewswireBEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ:LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ:PNT) today announced statistically significant topline
- 2y agoLLYPNTLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023PR NewswireEli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
- 2y agoLLYPNTLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023PR NewswireEli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
- 2y agoONCYEXELMRTXLLY+1Improving Survival Rates: Biotech Innovations in Pancreatic Cancer TreatmentPR NewswireUSA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a...
- 2y agoLLYPNTLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023PR NewswireEli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
- 2y agoLLYPNTLilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT BiopharmaPR NewswireEli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect...
- 2y agoLLYPNTPOINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewswireINDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing
- 3y agoLLYPNTLilly Announces Extension of Tender Offer to Acquire POINT BiopharmaPR NewswireEli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
- 3y agoPNTVERYMRTXORTXMoore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 3y agoACERLVOXPNTTWNKMoore Kuehn Encourages TWNK, LVOX, ACER, and PNT Investors to Contact Law FirmPR NewswireNEW YORK, Oct. 13, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoLABLVOXPNTVERYMoore Kuehn Encourages VERY, PNT, LAB, and LVOX Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoWRBYTREXLLYPNT+6Stocks making the biggest moves midday: Meta, Warby Parker, McCormick and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 3y ago11V-FFWMGPNTWRBY+5Stocks making the biggest moves premarket: Warby Parker, HP, Point Biopharma and moreCNBCThese are the stocks posting the largest moves in premarket trading.
- 3y agoLLYPNTLilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand TherapiesPR NewswireINDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and POINT Biopharma Global, Inc. (NASDAQ:PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company
- 3y agoPNTPOINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted RadioligandsGlobeNewswireINDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global
- 3y agoPNTPOINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewswireEnrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed
- 3y agoPNTITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177GlobeNewswireGarching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ:PNT) ("POINT"), a
- 3y agoPNTPOINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled RadioligandsGlobeNewswireINDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to
- 3y agoPNTPOINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI's Annual CongressGlobeNewswireAuger electron and beta emitting isotope terbium-161 was paired with POINT's FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555 Preclinical
- 3y agoPNTPOINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of DirectorsGlobeNewswireINDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing
- 3y agoPNTPOINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023GlobeNewswireRegister online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company
- 3y agoPNTPropulsion of Neuroendocrine Tumors Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain | DelveInsightGlobeNewswireNew York, USA, May 29, 2023 (GLOBE NEWSWIRE) -- Propulsion of Neuroendocrine Tumors Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain | DelveInsight The prevalence of
- 3y agoPNTPOINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCOGlobeNewswirePNT2004 program's phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25th Poster to be available starting at 9:00 AM ET, June 3rd INDIANAPOLIS, May 25, 2023 (GLOBE
- 3y agoPNTPOINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope ManufacturerGlobeNewswireINDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to
- 3y agoPNTPOINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewswireU.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023 Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp.
- 3y agoLNTHPNTLantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate CancerGlobeNewswireBEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and
- 3y agoLNTHPNTLantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate CancerGlobeNewswireBEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and
- 3y agoPNTEckert & Ziegler to Supply POINT Biopharma with Actinium-225GlobeNewswireBERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (("POINT", NASDAQ:PNT) have signed an agreement on the supply
- 3y agoLNTHPNTPOINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsGlobeNewswireSigned Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational
- 3y agoPNTPOINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)GlobeNewswireINDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing
- 3y agoPNTPOINT Biopharma to Participate in Upcoming Investor ConferencesGlobeNewswireINDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing
- 3y agoLNTHPNTPOINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH TrialGlobeNewswireINDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing
- 3y agoLNTHPNTPOINT Biopharma Announces Closing of Agreements with Lantheus HoldingsGlobeNewswireINDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. ("POINT") (NASDAQ:PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today
- 3y agoPNTPOINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with ImmunotherapyGlobeNewswireCombining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model 177Lu-PNT6555, the lead of
- 3y agoLNTHPNTPOINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus HoldingsGlobeNewswireINDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing
- 3y agoLNTHPNTLantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003GlobeNewswireCollaboration pairs POINT's expertise in next generation radioligand development and manufacturing with Lantheus' commercial leadership in PSMA PET and radiopharmaceuticals Expands Lantheus' portfolio with license of
- 4y agoPNTPOINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM's Annual CongressGlobeNewswirePNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA submission for PNT2001
- 4y agoPNTPOINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common StockGlobeNewswireINDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the closing
- 4y agoPNTPOINT Biopharma Prices Public Offering of Common StockGlobeNewswireINDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the pricing
- 4y agoPNTPOINT Biopharma Announces Proposed Public Offering of Common StockGlobeNewswireINDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that it has
- 4y agoPNTPOINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022GlobeNewswireNewly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR) was achieved in 60% of the 10 participants with e